The International Drug Repurposing Conference (#iDR24): Bridging Boundaries for Innovative Drug Repurposing, co-organized by REMEDi4ALL Consortium, Beacon for Rare Diseases, and MeRIT will be held on 6-7 March 2024 in Barcelona.
Drug repurposing consists of finding new therapeutic uses for existing medicines, building on the knowledge previously generated on safety and effectiveness for a specific drug. This means that scientific knowledge and resources are used efficiently, and research can move faster to provide patients with innovative therapeutic options where no treatments are available.
The conference showcases how patient communities, researchers, industry, and health authorities can benefit from cutting-edge drug repurposing.
Laurent Martin, ORPHELIA Pharma’s Chief Pharmaceutical Affairs Officer, will contribute to the discussion with the story and market access of Kigabeq, the first pediatric formulation of vigabatrin for the treatment of a rare form of encephalopathic epilepsy: West syndrome.
More information can be found at: https://remedi4all.org/international-drug-repurposing-conference/
LinkedIn: https://www.linkedin.com/feed/update/urn:li:share:7170693183050346496/
